WO2009105669A3 - Angiogenesis inhibition - Google Patents

Angiogenesis inhibition Download PDF

Info

Publication number
WO2009105669A3
WO2009105669A3 PCT/US2009/034709 US2009034709W WO2009105669A3 WO 2009105669 A3 WO2009105669 A3 WO 2009105669A3 US 2009034709 W US2009034709 W US 2009034709W WO 2009105669 A3 WO2009105669 A3 WO 2009105669A3
Authority
WO
WIPO (PCT)
Prior art keywords
heavy chain
vectors encoding
fusion proteins
igg heavy
chain molecule
Prior art date
Application number
PCT/US2009/034709
Other languages
French (fr)
Other versions
WO2009105669A2 (en
Inventor
Abraham Scaria
Samuel Wadsworth
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Priority to BRPI0908496A priority Critical patent/BRPI0908496A2/en
Priority to CN2009801059368A priority patent/CN101951925A/en
Priority to JP2010547799A priority patent/JP2011512417A/en
Publication of WO2009105669A2 publication Critical patent/WO2009105669A2/en
Publication of WO2009105669A3 publication Critical patent/WO2009105669A3/en
Priority to IL207641A priority patent/IL207641A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Fusion proteins comprising a functional polypeptide, a linker and an IgG heavy chain molecule, and vectors encoding such fusion proteins, are provided for inhibiting angiogenesis in individuals with pathological conditions related to neovascularization. In particular, vectors encoding a fusion VEGF antagonist comprising a VEGF receptor fused to an IgG heavy chain molecule is provided to treat ocular diseases in a mammal.
PCT/US2009/034709 2008-02-20 2009-02-20 Angiogenesis inhibition WO2009105669A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BRPI0908496A BRPI0908496A2 (en) 2008-02-20 2009-02-20 angiogenesis inhibition
CN2009801059368A CN101951925A (en) 2008-02-20 2009-02-20 Angiogenesis inhibition
JP2010547799A JP2011512417A (en) 2008-02-20 2009-02-20 Inhibition of angiogenesis
IL207641A IL207641A0 (en) 2008-02-20 2010-08-16 Compositions comprising nucleic acids encoding vegf antagonists for use in treating ocular disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US3007208P 2008-02-20 2008-02-20
US61/030,072 2008-02-20
US3454608P 2008-03-07 2008-03-07
US61/034,546 2008-03-07
US5663208P 2008-05-28 2008-05-28
US61/056,632 2008-05-28

Publications (2)

Publication Number Publication Date
WO2009105669A2 WO2009105669A2 (en) 2009-08-27
WO2009105669A3 true WO2009105669A3 (en) 2009-12-17

Family

ID=40986215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/034709 WO2009105669A2 (en) 2008-02-20 2009-02-20 Angiogenesis inhibition

Country Status (5)

Country Link
JP (1) JP2011512417A (en)
CN (1) CN101951925A (en)
BR (1) BRPI0908496A2 (en)
IL (1) IL207641A0 (en)
WO (1) WO2009105669A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2726101T1 (en) 2011-06-30 2018-12-31 Genzyme Corporation Inhibitors of t-cell activation
TWI702955B (en) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 Treatment of amd using aav sflt-1
KR102228921B1 (en) * 2013-03-13 2021-03-16 젠자임 코포레이션 Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof
JP6719381B2 (en) * 2014-02-06 2020-07-08 ジェンザイム・コーポレーション Compositions and methods for treating and preventing macular degeneration
EP3119798B1 (en) 2014-03-17 2020-08-05 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016005381A1 (en) * 2014-07-10 2016-01-14 Bayer Pharma Aktiengesellschaft Pdgfrbeta-fc fusion proteins and uses thereof
CN107405507B (en) 2015-03-02 2022-05-03 阿德夫拉姆生物技术股份有限公司 Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
KR101846306B1 (en) 2015-03-31 2018-05-18 일동제약(주) Pharmaceutical compositions for preventing and treating of eye diseases comprising fusion protein of tissue permeable peptide and anti-VEGF agent
EP3377101A4 (en) * 2015-11-19 2019-08-07 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
KR20180104635A (en) 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 Antibodies and conjugates thereof
KR101685532B1 (en) * 2016-04-26 2016-12-13 한국프라임제약주식회사 A VEGFR fusion protein
GB201806333D0 (en) * 2018-04-18 2018-05-30 Glaxosmithkline Ip Dev Ltd Parvovirus vector production
CN108671229B (en) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 Pharmaceutical composition preparation of recombinant human vascular endothelial growth factor receptor-antibody fusion protein
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN114181972A (en) * 2021-11-23 2022-03-15 上海本导基因技术有限公司 Lentiviral vectors suitable for gene therapy of refractory angiogenic eye diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088936A1 (en) * 2002-05-01 2006-04-27 Warrington Kenneth H Raav expression systems for genetic modification of specific capsid proteins
US20070224178A1 (en) * 2004-09-13 2007-09-27 Abraham Scaria Multimeric constructs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088936A1 (en) * 2002-05-01 2006-04-27 Warrington Kenneth H Raav expression systems for genetic modification of specific capsid proteins
US20070224178A1 (en) * 2004-09-13 2007-09-27 Abraham Scaria Multimeric constructs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAINBRIDGE ET AL.: "Gene therapy for ocular angiogenesis'", CLINICAL SCIENCE, vol. 104, 2003, pages 561 - 575 *

Also Published As

Publication number Publication date
WO2009105669A2 (en) 2009-08-27
CN101951925A (en) 2011-01-19
IL207641A0 (en) 2010-12-30
JP2011512417A (en) 2011-04-21
BRPI0908496A2 (en) 2019-01-15

Similar Documents

Publication Publication Date Title
WO2009105669A3 (en) Angiogenesis inhibition
WO2014100439A3 (en) B7-h4 specific antibodies, and compositions and methods of use thereof
JP2012025766A5 (en)
JP2012025737A5 (en)
HK1219284A1 (en) Immunoglobulin fusion proteins
WO2010003101A3 (en) Il6 immunotherapeutics
IL197636B (en) Isolated human monoclonal antibodies specifically binding human il-17 receptor
WO2007130302A3 (en) Rage fusion proteins, formulations, and methods of use thereof
WO2013041844A3 (en) Antibodies, variable domains & chains tailored for human use
PE20121129A1 (en) HUMAN ANTIBODIES OF HIGH AFFINITY FOR HUMAN ANGIOPOYETIN-2
IL220164B (en) Method of producing purified antibody, antibody fragment, or fc fusion protein, using affinity chromatography matrix
WO2007133811A3 (en) Cd47 related compositions and methods for treating immunological diseases and disorders
IL210175A0 (en) Fn14/trail fusion proteins
WO2013043933A3 (en) Cd27l antigen binding proteins
BRPI0807480A2 (en) CONNECTING, IMMUNOGLOBULIN G, COMPOSITION AND FUSION PROTEIN
SI2162467T1 (en) Polypeptides, antibody variable domains & antagonists
WO2011032161A3 (en) Vaccines directed to langerhans cells
HK1209135A1 (en) Antibody targeting osteoclast-related protein siglec-15 siglec-15
WO2008157378A8 (en) Rage fusion proteins
NZ601117A (en) Biparatopic abeta binding polypeptides
EP2000483A4 (en) Vegf receptor fusion protein and use thereof
WO2015007536A3 (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
BRPI1016204A2 (en) antibody fusion proteins with modified fcrn binding sites
WO2007115230A3 (en) A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells
IL214648A0 (en) Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980105936.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09713015

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2834/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 207641

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2010547799

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/009178

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009713015

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0908496

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100819